PriceTargets.com logo

SELLAS Life Sciences Group - SLS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 98.10%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.51 As of 04/19/2024 04:27 PM ET
▼ -0.0056 (-0.37%)

This chart shows the closing price for SLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SELLAS Life Sciences Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLS

Analyst Price Target is $3.00
▲ +98.10% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for SELLAS Life Sciences Group in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 98.10% upside from the last price of $1.51.

This chart shows the closing price for SLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in SELLAS Life Sciences Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$3.00Low
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$3.00Low
4/18/2023National Bank FinancialReiterated RatingOutperform-SpeculativeN/A
11/15/2022Alliance Global PartnersLower TargetBuy$14.00 ➝ $8.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
6/28/2022Cantor FitzgeraldLower TargetOverweight$10.00 ➝ $6.00Low
4/13/2022National Bank FinancialReiterated RatingOutperform Spec OverweightN/A
4/7/2022Alliance Global PartnersLower Target$16.50 ➝ $14.00Low
12/3/2021Cantor FitzgeraldLower TargetOverweight$18.00 ➝ $16.00High
11/12/2021Maxim GroupInitiated CoverageBuy$21.00High
7/21/2021Cantor FitzgeraldInitiated CoverageOverweight$18.00High
6/25/2021Maxim GroupBoost TargetPositive ➝ Buy$12.00 ➝ $21.00Medium
6/21/2021Royal Bank of CanadaInitiated CoverageOutperform$18.00Low
6/3/2021Alliance Global PartnersBoost TargetBuy$8.00 ➝ $16.50Medium
5/14/2021Maxim GroupReiterated RatingBuy$12.00N/A
2/27/2020Maxim GroupReiterated RatingBuy$12.00N/A
11/15/2019Maxim GroupUpgradeHold ➝ BuyN/A
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

SELLAS Life Sciences Group logo
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $1.51
Low: $1.47
High: $1.57

50 Day Range

MA: $1.11
Low: $0.70
High: $1.55

52 Week Range

Now: $1.51
Low: $0.50
High: $1.91

Volume

1,377,396 shs

Average Volume

1,456,176 shs

Market Capitalization

$85.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.35

Frequently Asked Questions

What sell-side analysts currently cover shares of SELLAS Life Sciences Group?

The following sell-side analysts have issued research reports on SELLAS Life Sciences Group in the last year: Cantor Fitzgerald.
View the latest analyst ratings for SLS.

What is the current price target for SELLAS Life Sciences Group?

1 Wall Street analysts have set twelve-month price targets for SELLAS Life Sciences Group in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 98.1%. Cantor Fitzgerald has the highest price target set, predicting SLS will reach $3.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $3.00 for SELLAS Life Sciences Group in the next year.
View the latest price targets for SLS.

What is the current consensus analyst rating for SELLAS Life Sciences Group?

SELLAS Life Sciences Group currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLS will outperform the market and that investors should add to their positions of SELLAS Life Sciences Group.
View the latest ratings for SLS.

What other companies compete with SELLAS Life Sciences Group?

Other companies that are similar to SELLAS Life Sciences Group include Leap Therapeutics, InflaRx, Anebulo Pharmaceuticals, Journey Medical and Assertio. Learn More about companies similar to SELLAS Life Sciences Group.

How do I contact SELLAS Life Sciences Group's investor relations team?

SELLAS Life Sciences Group's physical mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The company's listed phone number is (646) 200-5278 and its investor relations email address is [email protected]. The official website for SELLAS Life Sciences Group is www.sellaslifesciences.com. Learn More about contacing SELLAS Life Sciences Group investor relations.